CompanyTENXNasdaqChapel Hill, NC

Tenax Therapeutics, Inc.

Tenax Therapeutics develops levosimendan, a K-ATP channel activator/calcium sensitizer.

SEC EDGAR ClinicalTrials.gov tenaxthera.com

SCHEDULE 13G/ASep 11Latest SEC filing

Aug 10Latest story

August 2026

Tenax's TNX-103 misses primary endpoint in Phase 3 LEVEL trial for PH-HFpEF

Aug 10Clinical readoutTenax Therapeutics, Inc.TNX-103

July 2026

Tenax reports Q2 2026 results, confirms August LEVEL trial data and ESC presentation

Jul 31Quarterly updateTenax Therapeutics, Inc.

Tenax to present Phase 3 LEVEL trial data at ESC Congress 2026, expects topline results in August

Jul 2Clinical readoutTenax Therapeutics, Inc.

June 2026

Tenax and Orion finalize supply pact and sixth amendment for oral levosimendan

Jun 30PartnershipTenax Therapeutics, Inc.

Tenax Therapeutics amends executive pay deals, adopts new severance plans

Jun 29PeopleTenax Therapeutics, Inc.